Fast Facts

UPMC Hillman Cancer Center is internationally recognized for its leadership in the prevention, detection, diagnosis, and treatment of cancer. As the preeminent institution in western Pennsylvania for the delivery of cancer care, the performance of basic, translational, and clinical research, and the education of the next generation of cancer researchers and physicians, UPMC Hillman Cancer Center is exceptionally well positioned to contribute to the global effort to reduce the burden of cancer.

An Impressive Network
- More than 110,000 individuals treated each year - more than 37,000 are new patients
- One of the largest integrated community cancer networks in the United States with more than 60 centers in western Pennsylvania and Ohio
- More than 2,000 physicians, researchers, and staff

Driving Clinical Innovation
- Employs the latest innovative technologies, including intensity modulated radiation therapy (IMRT), treatments using RapidArc®, TrueBeam™ STx, CyberKnife®M6™, and positron emission tomography/computed tomography (PET-CT) planning, which was pioneered by UPMC physicians
- Created Via Oncology Pathways, a unique web-based technology to provide physicians with evidence-based clinical algorithms that standardize best-practice cancer treatments to optimize patient outcomes

A Strong Commitment to Research
- Western Pennsylvania’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center
- Ranked 14th in NCI funding among NCI-designated centers, which includes three competitive Specialized Program of Research Excellence (SPORE) cancer grants focusing on head and neck, lung, and skin cancers, and a shared grant in ovarian cancer, in collaboration with Roswell Park Cancer Institute
- Investigators are leaders in molecular and cellular cancer biology, cancer immunology, cancer virology, biobehavioral oncology, and cancer epidemiology, prevention, and therapeutics
- 10 NCI Cancer Center Support Grant (CCSG)-supported programs and 13 CCSG-supported shared resources that provide services to investigators at UPMC Hillman Cancer Center

Accolades
- University of Pittsburgh ranked fifth in NIH funding among all universities nationwide, receiving more than $476 million in NIH support in Fiscal Year 2017
- UPMC ranked 14th on the U.S. News & World Report Best Hospitals Honor Roll and ranked among the best in the country for cancer care in 2017
- UPMC Hillman Cancer Center comprises one of the largest networks across the U.S. to be recognized by accredited, independent organizations — including the American College of Radiation Oncology and Quality Oncology Practice Initiative — for quality, consistency, and outcomes in comprehensive cancer care.
Commercial Ventures
UPMC is actively forging long-term partnerships with technology and health care industry leaders, and acts as a hands-on equity partner, using its more than $14 billion integrated global health enterprise to develop and evaluate products and services designed to improve health care delivery.

- D3 Oncology Solutions focuses its services on enabling health care organizations to derive the benefits of advanced radiotherapy, such as IMRT, IGRT, SRS, and gated therapy, while easing the associated technical, educational, and staffing challenges for radiation therapy clinics.
- Via Oncology Pathways, created by UPMC Hillman Cancer Center, uses web-based technology to provide physicians with evidence-based clinical algorithms that standardize best-practice cancer treatment, optimize patient outcomes, minimize toxicities, and promote efficient resource utilization.

International Centers and Partnerships
UPMC Hillman Cancer Center has international locations at UPMC San Pietro FBF Advanced Radiotherapy Center and Salvator Mundi International Hospital in Rome, Italy, UPMC Whitfield Cancer Centre in Waterford, Ireland, and planned locations in Avellino, Italy (2018) and Cork, Ireland (2019). UPMC Hillman Cancer Center also collaborates with hospital systems around the world, sharing decades of expertise through clinical training, facilities management, and operational oversight to help develop and support high-quality cancer care services for their patients. Our collaborations include:

- National Research Oncology Center
  Astana, Kazakhstan
- RusSing Med Holdings
  Moscow, Russia

By the Numbers

Research
Clinical Trials
Active Clinical Trials at
UPMC Hillman Cancer Center ......................... 511
Patient Accruals for FY 2017 ...................... 5,462

Grants and Funding
Research Funding Received in FY 2017 ...... $156,962,149

Research Publications
Publications Over the Last Five Years .......... 5,750
Faculty Researchers ............................... 328

Clinical Care
Physicians and Providers
Medical Oncology/Hematology ..................... 224
Radiation Oncology ............................... 33
Surgical Oncology ................................ 27

UPMC Hillman Cancer Center**
Staff .................................................. 1,446

Treatment Centers
Medical Oncology Centers ......................... 38
Radiation Oncology Centers ....................... 22
Dual Centers ....................................... 3
International Centers and Partnerships ........ 7
Total Centers ...................................... 70

Net Patient Revenue** ................................ $762,489,796

**Total includes medical oncology and radiation oncology physicians for FY 2017.

Unique Patients Receiving Services/Treatments

UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.